CRBU Profile
Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on advancing genome-edited allogeneic cell therapies to address a range of challenging cancers. Established in 2011 and headquartered in Berkeley, California, the company operates internationally with a strong emphasis on developing innovative treatments for hematologic malignancies and solid tumors. Caribou's core technology leverages its proprietary genome-editing platform to create targeted and effective therapies for patients with severe forms of cancer.
The company's lead product candidates include CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently in Phase 1 clinical trials for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. Another prominent candidate, CB-011, is an allogeneic anti-BCMA CAR-T cell therapy designed for treating relapsed or refractory multiple myeloma. Both therapies utilize advanced cell engineering techniques to enhance targeting precision and improve therapeutic outcomes for patients with these complex conditions.
Caribou is also developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy targeting relapsed or refractory acute myeloid leukemia (AML), and CB-020, an allogeneic CAR-NK cell therapy aimed at treating solid tumors. These therapies are in various stages of preclinical and early clinical development, reflecting Caribou's commitment to expanding its pipeline of next-generation cancer treatments. The focus on solid tumors and AML underscores the company's dedication to addressing unmet medical needs across a broad spectrum of oncology indications.
The company has established a strategic collaboration with AbbVie Manufacturing Management Unlimited Company to advance its CAR-T cell therapies, leveraging AbbVie's expertise in manufacturing and development. This partnership enhances Caribou's capabilities and accelerates the path to bringing innovative therapies to market. As Caribou Biosciences continues to expand its research and development efforts, it remains at the forefront of genomic medicine and cellular therapies, striving to improve outcomes for patients battling severe cancers worldwide.
|
